Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN W HALPERN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1821160599
CMS profile
310128
Location
SANTA ROSA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,618.33

96 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,607.87 95
Education $10.46 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN W HALPERN

NPI 1821160599 · CMS profile ID 310128

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SANTA ROSA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821160599?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN W HALPERN, NPI 1821160599, CMS profile ID 310128. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821160599?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEPHEN W HALPERN, NPI 1821160599, CMS profile ID 310128. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821160599?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEPHEN W HALPERN, NPI 1821160599, CMS profile ID 310128, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1821160599?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

96 matching records · $2,618.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 96 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–96 of 96.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.0206/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104419127 CMS
Actelion Pharmaceuticals US, Inc. $19.6506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078872556 CMS
Amgen Inc. $10.4606/04/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115696118 CMS
Amgen Inc. $13.0206/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115696073 CMS
Amgen Inc. $30.1105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115696064 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7.7305/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118167960 CMS
PFIZER INC. $17.9605/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131417835 CMS
Merck Sharp & Dohme LLC $17.7005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141751182 CMS
United Therapeutics Corporation $32.6205/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149454432 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118167968 CMS
Esperion Therapeutics, Inc. $14.8205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129437610 CMS
PFIZER INC. $14.8105/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131315053 CMS
AstraZeneca Pharmaceuticals LP $21.0204/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105774600 CMS
SANOFI-AVENTIS U.S. LLC $20.2504/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139570836 CMS
HEARTFLOW, INC. $185.4204/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154167264 CMS
E.R. Squibb & Sons, L.L.C. $3.4204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292154 CMS
E.R. Squibb & Sons, L.L.C. $22.7104/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292162 CMS
Amgen Inc. $17.8504/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115696056 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.5804/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118167974 CMS
Esperion Therapeutics, Inc. $14.2604/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129437608 CMS
Merck Sharp & Dohme LLC $17.7104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141751188 CMS
PFIZER INC. $19.1804/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131351369 CMS
Actelion Pharmaceuticals US, Inc. $13.8004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078872586 CMS
AstraZeneca Pharmaceuticals LP $17.0504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104497348 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.3104/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086114552 CMS
Merck Sharp & Dohme LLC $17.9303/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141751192 CMS
United Therapeutics Corporation $14.2003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149466064 CMS
E.R. Squibb & Sons, L.L.C. $30.8103/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292152 CMS
Edwards Lifesciences Corporation $139.5503/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138893281 CMS
Boston Scientific Corporation $22.3303/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092737336 CMS
Bayer Healthcare Pharmaceuticals Inc. $30.4303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086217235 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.7303/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080702886 CMS
Abbott Laboratories $24.1703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125289424 CMS
Merck Sharp & Dohme LLC $27.9002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141953037 CMS
E.R. Squibb & Sons, L.L.C. $29.1302/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292150 CMS
Amgen Inc. $8.3802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115696048 CMS
AstraZeneca Pharmaceuticals LP $19.4902/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105566890 CMS
Alnylam Pharmaceuticals Inc. $22.5102/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125824811 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.7702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118167962 CMS
E.R. Squibb & Sons, L.L.C. $14.2801/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292134 CMS
Actelion Pharmaceuticals US, Inc. $28.3301/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078872564 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $5.6501/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118167956 CMS
Esperion Therapeutics, Inc. $16.9701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129437606 CMS
AstraZeneca Pharmaceuticals LP $14.9901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105880880 CMS
E.R. Squibb & Sons, L.L.C. $9.9501/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101292130 CMS
Kiniksa Pharmaceuticals International, plc $25.0301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154876645 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,946.59 113
PY2020 $640.24 37
PY2021 $1,131.29 50
PY2022 $1,500.89 54
PY2023 $1,916.47 68
PY2024 $2,618.33 96
PY2025 $1,625.46 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $361,795.95 152
PY2024 Principal investigator $434,148.11 26
PY2023 Principal investigator $79,754.49 18
PY2022 Principal investigator $124,874.02 32
PY2021 Principal investigator $40,666.62 14
PY2020 Principal investigator $51,692.43 46
PY2019 Principal investigator $46,211.75 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

152 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778990
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 12/17/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778992
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 12/17/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778994
Principal investigator 1 Janssen Research & Development, LLC $7,308.00 12/15/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180861
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 12/12/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220816390
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,677.00 12/04/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810990
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778974
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778976
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778978
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778980
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778982
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778984
Principal investigator 1 Janssen Research & Development, LLC $3,174.00 11/21/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181177
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778960
Principal investigator 1 Boehringer Ingelheim International GmbH $64.50 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778964
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778970
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778972
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 10/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778986
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 10/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778988
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,711.65 10/23/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810988
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/22/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180707
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778948
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778950
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778952
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778954
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778956
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778958
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778944
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 09/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778946
Principal investigator 1 Janssen Research & Development, LLC $754.00 09/19/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,758.95 09/04/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810986
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778912
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778914
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778916
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778918
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778920
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778938
Principal investigator 1 Janssen Research & Development, LLC $1,987.00 08/25/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180946
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,858.65 08/05/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810984
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778902
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778904
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778906
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778908
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778910
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778932
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778936
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 07/28/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778940
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 07/28/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778942
Principal investigator 1 Janssen Research & Development, LLC $1,092.00 07/23/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 07/09/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810976
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 07/09/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810978
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 07/09/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810980
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 07/09/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810982
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $68.80 07/02/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220816388
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778922
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778924
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778926
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778928
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778930
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778934
Principal investigator 1 Amgen Inc. $74,725.72 06/30/2025 Non-covered Recipient Entity
NORTHBAY CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246645436
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,953.45 06/26/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810974
Principal investigator 1 Janssen Research & Development, LLC $828.00 06/25/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181072
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778894
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778896
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778898
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 06/24/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778900
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,100.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810960
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810962
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810964
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810966
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810968
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810970
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/24/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810972
Principal investigator 1 Janssen Research & Development, LLC $2,340.00 06/20/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181170
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810946
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810948
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810950
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810952
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 06/03/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810956
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778872
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778874
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778876
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778878
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778880
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778882
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778884
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,674.70 05/28/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810944
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778886
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 05/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778888
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 05/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778890
Principal investigator 1 Boehringer Ingelheim International GmbH $2.76 05/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778892
Principal investigator 1 Janssen Research & Development, LLC $1,467.00 05/23/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181005
Principal investigator 1 Janssen Research & Development, LLC $2,147.00 05/16/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181025
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778860
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778862
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778864
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778866
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778868
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778870
Principal investigator 1 Janssen Research & Development, LLC $3,174.00 04/23/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181138
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,307.50 04/11/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778848
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778850
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778852
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778854
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778856
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778858
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778844
Principal investigator 1 Janssen Research & Development, LLC $1,993.00 03/17/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181047
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42,467.85 03/07/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810940
Principal investigator 1 Janssen Research & Development, LLC $2,372.00 03/03/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175181019
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778816
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778818
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778820
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778824
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778826
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778832
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778834
Principal investigator 1 Boehringer Ingelheim International GmbH $663.30 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778836
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778838
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778840
Principal investigator 1 Boehringer Ingelheim International GmbH $22.08 02/25/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778842
Principal investigator 1 Janssen Research & Development, LLC $4,516.00 02/24/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180767
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $43.00 02/21/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220816386
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,693.86 02/14/2025 Non-covered Recipient Entity
Northbay Clinical Research
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235995281
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778800
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778802
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778806
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778808
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778810
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778812
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778814
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778828
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778830
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,971.20 01/27/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810938
Principal investigator 1 Janssen Research & Development, LLC $1,893.00 01/22/2025 Non-covered Recipient Entity
Northbay Clinic Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175180777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,010.85 01/17/2025 Non-covered Recipient Entity
NorthBay Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220810936
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 01/09/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220816384
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778790
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778792
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778794
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778796
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778798
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
North Bay Cardiology Inc
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220778846